Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
-
Published:2024-07-23
Issue:
Volume:
Page:
-
ISSN:0300-8177
-
Container-title:Molecular and Cellular Biochemistry
-
language:en
-
Short-container-title:Mol Cell Biochem
Author:
Ionică Loredana N.,Buriman Darius G.,Lința Adina V.,Șoșdean Raluca,Lascu Ana,Streian Caius G.,Feier Horea B.,Petrescu Lucian,Mozoș Ioana M.,Sturza Adrian,Muntean Danina M.
Abstract
AbstractThe sodium-glucose-cotransporter 2 inhibitors (SGLT2i) are the blockbuster antidiabetic drugs that exert cardiovascular protection via pleiotropic effects. We have previously demonstrated that empagliflozin decreased monoamine oxidase (MAO) expression and oxidative stress in human mammary arteries. The present study performed in overweight, non-diabetic cardiac patients was aimed to assess whether the two widely prescribed SGLT2i decrease atrial MAO expression and alleviate oxidative stress elicited by exposure to angiotensin 2 (ANG2) and high glucose (GLUC). Right atrial appendages isolated during cardiac surgery were incubated ex vivo with either empagliflozin or dapagliflozin (1, 10 µm, 12 h) in the presence or absence of ANG2 (100 nm) and GLUC (400 mg/dL) and used for the evaluation of MAO-A and MAO-B expression and ROS production. Stimulation with ANG2 and GLUC increased atrial expression of both MAOs and oxidative stress; the effects were significantly decreased by the SGLT2i. Atrial oxidative stress positively correlated with the echocardiographic size of heart chambers and negatively with the left ventricular ejection fraction. In overweight patients, MAO contributes to cardiac oxidative stress in basal conditions and those that mimicked the renin–angiotensin system activation and hyperglycemia and can be targeted with empagliflozin and dapagliflozin, as novel off-target class effect of the SGLT2i.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, Lega JC, Gueyffier F, Cucherat M, Grenet G (2022) SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 65:2000–2010. https://doi.org/10.1007/s00125-022-05773-8 2. Delgado E, Jódar E, Mezquita-Raya P, Moreno-Pérez Ó (2022) Benefits of SGLT2i for the treatment of heart failure irrespective of diabetes diagnosis: a state-of-the-art review. Diabetes Ther 13:19–34. https://doi.org/10.1007/s13300-022-01278-0 3. Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, Liberale L (2024) SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res 120:443–460. https://doi.org/10.1093/cvr/cvae047 4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 24:4–131. https://doi.org/10.1002/ejhf.2333 5. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK (2023) 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44:3627–3639. https://doi.org/10.1093/eurheartj/ehad195
|
|